Assessment of In Vivo siRNA Delivery in Cancer Mouse Models
RNA interference (RNAi) has rapidly become a powerful tool for target discovery and therapeutics. Small interfering RNAs (siRNAs) are highly effective in mediating sequence-specific gene silencing. However, the major obstacle for using siRNAs as cancer therapeutics is their systemic delivery from the administration site to target cells in vivo. This chapter describes approaches to deliver siRNA effectively for cancer treatment and discusses in detail the current methods to assess pharmacokinetics and biodistribution of siRNAs in vivo.
Key wordssiRNA Ovarian cancer Delivery Cancer therapy Stem-loop RT-PCR
H.H. is supported by JSPS Postdoctoral Fellowships for Research Abroad. S.Y.W. is supported by Ovarian Cancer Research Fund, Inc., Foundation for Women’s Cancer, and Cancer Prevention Research Institute of Texas training grants (RP101502 and RP101489). Portions of this work were supported by NIH grants (P50CA083639, CA109298, P50CA098258, U54CA151668, UH2TR000943, CA016672, U54CA96300, and U54CA96297), CPRIT (RP110595 and RP120214), an Ovarian Cancer Research Fund Program Project Development Grant, the Betty Ann Asche Murray Distinguished Professorship, the RGK Foundation, the Gilder Foundation, the Judi A. Rees Ovarian Cancer Research Fund, the Chapman Foundation, and the Meyer and Ida Gordon Foundation. This research was also supported, in part, by the Blanton-Davis Ovarian Cancer Research Program.